Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population
- 211 Downloads
The decision to proceed to biopsy for the diagnosis of prostate cancer in clinical practice is a difficult one. Prostate cancer risk calculators allow for a systematic approach to the use of patient information to predict a patient’s likelihood of prostate cancer.
In this paper, we validate the two leading prostate cancer risk calculators, the prostate cancer prevention trial (PCPT) and the European Randomized Study of Screening for Prostate Cancer (ERSPC) in an Irish population.
Data were collected for 337 men referred to one tertiary referral center in Ireland. Calibration analysis, ROC analysis and decision curve analysis were undertaken to ascertain the performance of the PCPT and the ERSPC risk calculators in this cohort.
Of 337 consecutive biopsies, cancer was subsequently diagnosed in 146 men (43 %), 98 (67 %) of which were high grade. The AUC for the PCPT and ERSPC risk calculators were 0.68 and 0.66, respectively for the prediction of prostate cancer. Each calculator was sufficiently calibrated in this cohort. Decision curve analysis demonstrated a net benefit via the use of the PCPT and ERSPC risk calculators in the diagnosis of prostate cancer.
The PCPT and ERSPC risk calculators achieve a statistically significant prediction of prostate cancer in this Irish population. This study provides external validation for these calculators, and therefore these tools can be used to aid in clinical decision making.
KeywordsBiopsy Decision support techniques Prostatic neoplasm Risk
RWG Watson and D. J. Lundon received funding from the Prostate Cancer Research Consortium (PCRC) under the Irish Cancer Society, the Urology Foundation and the Irish Research Council. RW Foley received funding through the UCD School of Medicine Intercalated MSc. Medical Science Scholarship Programme.
Conflict of interest
- 1.National Cancer Registry (2014) Cancer in Ireland 1994–2011: annual report of the National Cancer Registry 2014. http://www.ncri.ie/sites/ncri/files/pubs/annualreport2014.pdf. Accessed 2 Jul 2014
- 2.National Cancer Registry (2010) Cancer trends. No. 3. Recent trends in prostate cancerGoogle Scholar
- 4.National Institute for Health and Care Excellence (2014) Prostate cancer: diagnosis and treatment, 1-recommendations. [CG175]. http://www.nice.org.uk/guidance/cg175. Accessed 9 Mar 2015
- 8.SWOP (2014) SWOP: prostate cancer risk calculator (based on ERSPC). http://www.prostatecancer-riskcalculator.com/. Accessed 3 Jul 2014
- 10.Zhu Y, Wang J-Y, Shen Y-J, Dai B, Ma C-G, Xiao W-J, Lin G-W, Yao X-D, Zhang S-L, Ye D-W (2012) External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening For Prostate Cancer risk calculators in a Chinese cohort. Asian J Androl 14:738–744PubMedCentralCrossRefPubMedGoogle Scholar
- 14.Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane database Syst Rev 1:4720Google Scholar
- 15.Irish National Cancer Control Programme (2011) NCCP Prostate cancer referral guideline. http://www.healthlink.ie/Oncology/NCCP. Prostate cancer referral guideline version 1.3 Jan 2011.pdf
- 18.PCPT (2014) Individualized risk assessment of prostate cancer (based on PCPT). http://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp. Accessed 3 Jul 2014
- 23.Van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Roobol MJ (2012) Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer 48:1809–1815CrossRefPubMedGoogle Scholar